Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA5 | P31644 | 5/20 | 0.53 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | PARG | Q86W56 | 3/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.43 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.43 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 3/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466124 | 0.88 | CMA1 (0.46) | GABRA5GABRA1PARGMAPK8MAPK9 | |
| SCHEMBL7460713 | 0.88 | MAPK8 (0.55) | KMT2AMAPK8MAPK9CMA1SRC | |
| SCHEMBL7470753 | 0.84 | NAMPT (0.55) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7461866 | 0.84 | MEN1 (0.48) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7461329 | 0.82 | CMA1 (0.46) | KMT2APARGMAPK8MAPK9CMA1 | |
| SCHEMBL7467427 | 0.80 | ALDH1A1 (0.47) | GABRA5GABRA1KMT2APARGMAPK8 | |
| SCHEMBL7468043 | 0.80 | MAPT (0.48) | KMT2ALMNASMN1; SMN2 | |
| SCHEMBL7470273 | 0.80 | CCR2 (0.47) | KMT2APARGMAPK8MAPK9CMA1 | |
| SCHEMBL7472478 | 0.80 | CCR2 (0.50) | KMT2AMAPK8MAPK9CMA1SMN1; SMN2 | |
| SCHEMBL7468517 | 0.79 | HDAC6 (0.52) | KMT2AMAPK8MAPK9CMA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | MICROBIA, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2006102069-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND GASTROINTESTINAL DISORDERS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | INOUE JUN (JP) | 2004-05-06 | — | — | US | disclosed |
| EP-1224945-A1 | TENSION-RELIEVING AGENTS FOR CILIARY MUSCLE | Senju Pharmaceutical Co., Ltd. (JP) | 2002-07-24 | — | — | EP | disclosed |
| EP-0795548-B1 | QUINAZOLINE DERIVATIVES AND USE THEREOF | SUNTORY LTD (JP) | 2002-07-03 | — | — | EP | disclosed |
| EP-1112749-A2 | PREVENTIVES OR REMEDIES FOR EYE CIRCULATORY FAILURE | Senju Pharmaceutical Co., Ltd. (JP) | 2001-07-04 | — | — | EP | disclosed |
| US-5814631-A | CHYMASE INHIBITOR, CARDIVASCULAR | SUNTORY LIMITED (JP) | 1998-09-29 | — | — | US | disclosed |
| EP-0795548-A1 | QUINAZOLINE DERIVATIVES AND USE THEREOF | SUNTORY LIMITED (JP) | 1997-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040086537-A1 | Prophylactic or threapeutic composition for ocular circulation disorders | CMA1, THOP1, TPSAB1 | GABRA5 2781/4885GABRA1 3048/4885KMT2A 4655/4885 |
| US-20090054319-A1 | Methods and Compositions for the Treatment of Hypertension and Gastrointestinal Disorders | PTGIS, PTGIR, GRPR | GABRA5 285/4885GABRA1 396/4885KMT2A 4822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.